Evaluating Pre-Treatment Vestibular Physical Therapy Rehab for Patients With Vestibular Schwannomas

Inclusion Criteria:

1. Provision of signed and dated informed consent form

2. Male or female participants ≥18 years of age.

3. Initial diagnosis of a Vestibular Schwannoma confirmed by a physician with aninternal auditory canal (IAC) MRI, in accordance with standard or institutionalpractice

4. VS patients who present with a tumor size ≤2.5 cm and will be treated with surgeryor SRS

5. Eastern Cooperative Oncology Group (ECOG) Performance Status <2

6. Within 14 days of study registration, participants must have normal laboratoryvalues that support safe treatment, at the discretion of the treating investigator

7. Be willing to adhere to outlined study protocol criteria and complete self-reportedquestionnaires (translations may be made available if the patient' primary languageis not English).

8. For females of reproductive potential: must have a negative urine or serum pregnancytest 7 prior to enrollment and agreement to use of highly effective contraceptionmethod during study participation and for an additional 24 weeks after thecompletion of stereotactic radiosurgery.

Exclusion Criteria:

1. Subjects less than 18 years of age

2. Prior treatment of VS including radiotherapy or surgery or treatment for diseaserecurrence or planned salvage procedure

3. Pre-existing, secondary vestibular diagnoses (e.g., Meniere's, intractable benignparoxysmal positional vertigo (BPPV), vestibular migraine, 3PD).

4. Other medical comorbidities know to significantly impair/affect balance and/orvestibular function testing (e.g., prior stroke, uncorrected visual impairment orblindness, etc.)

5. Anticipated radiation other than stereotactic (fractionated)

6. Inability to undergo MRI scans safely

7. Allergy to Gadolinium contrast used for MRI scans

8. Women of childbearing potential who are known to be pregnant or are unwilling to usean acceptable method of contraception from the time of informed consent untilcompletion of study related treatment and additional 24 weeks following stereotacticradiosurgery administration.